AtaiBeckley Inc. 4

Amir H. Kalali’s 4,666 common shares and a total of 455,968 stock options in AtaiBeckley Inc. were cancelled and cashed out for $6.75 per share (plus CVRs) in connection with Eli Lilly’s acquisition of the company.

On September 11, 2026, in connection with the closing of Eli Lilly’s acquisition of AtaiBeckley Inc., all of Amir H. Kalali’s equity interests in the company were cancelled and cashed out pursuant to the merger agreement. His 4,666 shares of common stock were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, and each of his stock option grants—64,000 options at $3.84, 64,000 options at $1.88, 103,000 options at $1.34, 103,000 options at $2.25, and 121,968 options at $4.50—was automatically cancelled and converted into a cash payment equal to the intrinsic value of the options based on the $6.75 merger price, together with one CVR for each underlying share. As a result of the merger consideration being delivered entirely in cash and CVRs rather than continuing equity, Kalali’s direct ownership of AtaiBeckley common stock and options became zero after the transaction, and the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036382

Alert Tier

6